sanofi-aventis

1 Onslow Street, Guildford, Surrey, GU1 4YS, UK
Telephone: +44 (0)1483 505 515
Fax: +44 (0)1483 535 432
Medical Information e-mail: uk-medicalinformation@sanofi-aventis.com

Patient Information Leaflet last updated on the eMC: 19/04/2011
PIL Tarivid IV Infusion Solution

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 19/04/2011 and displayed until Current
Reasons for adding or updating:
  • Change to side-effects
Updated on 21/09/2010 and displayed until 19/04/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to instructions about overdose
  • Change to side-effects
  • Change to drug interactions
  • Change to information about pregnancy or lactation
Updated on 30/07/2008 and displayed until 21/09/2010
Reasons for adding or updating:
  • Change due to user-testing of patient information
Updated on 29/04/2008 and displayed until 30/07/2008
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 31/08/2005 and displayed until 29/04/2008
Reasons for adding or updating:
  • Change to side-effects
Updated on 30/07/2002 and displayed until 31/08/2005
Reasons for adding or updating:
  • Update to PIL

Active Ingredients/Generics

 
   ofloxacin